Exagen
XGN

$3.14

8.19%

Market Cap: $54.6M

About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Employees: 179

Healthcare Medical Laboratories

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

9% more capital invested

Capital invested by funds: $10.6M [Q1] → $11.5M (+$915K) [Q2]

6% more funds holding

Funds holding: 31 [Q1] → 33 (+2) [Q2]

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

2.26% less ownership

Funds ownership: 38.79% [Q1] → 36.53% (-2.26%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for XGN.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about XGN published over the past 30 days

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global Healthcare Conference, which takes place September 17-19, 2024, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen's President and Chief Executive Officer and Jeff Black, Exagen's Chief Financial Officer, will participate in a fireside chat on Wednesday, September 18th, at 9:45 AM ET.

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

Zacks Investment Research

Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Exagen (XGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now

Zacks Investment Research

Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock

Exagen (XGN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock

Zacks Investment Research

Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?

Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?

Zacks Investment Research

Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain

Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript

Exagen, Inc. (NASDAQ:XGN ) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Ryan Douglas - IR John Aballi - President & CEO Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Daniel Brennan - TD Cowen Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Operator Greetings. Welcome to the Exagen Inc. Second Quarter 2024 Earnings Call.

Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago.

Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th Annual Growth Conference, which takes place August 13-15, 2024, at the InterContinental Boston Hotel in Boston, MA. John Aballi, Exagen's President and Chief Executive Officer will participate in a fireside chat on Wednesday, August 14th, at 2:30 PM ET. Interested parties may access the webcast of the presentation using a link on Exagen's website at https://investors.exagen.com/events.

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August.

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before the market opens on Monday, August 5, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

See News Rankings